FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a crystalline anhydrous form of (2S)-1-{(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl}-N-[4-(N'-methoxycarbamimidoyl)benzyl]azetidine-2-carboxamide of formula:
having X-ray powder diffraction pattern characterised by peaks of the values d 15.2 Å, 10.8 Å, 6.8 Å, 6.0 Å, 5.2 Å, 4.79 Å, 4.23 Å and 3.98 Å, which is applicable in a pharmaceutical composition as a thrombin inhibitor.
EFFECT: preparing the compound which is applicable in the pharmaceutical composition as a thrombin inhibitor.
6 cl, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL PREPARATION WITH MODIFIED ELUTION | 2003 |
|
RU2352323C2 |
| TIME-RELEASE PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2003 |
|
RU2474416C2 |
| PHARMACEUTICAL COMPOSITION | 2002 |
|
RU2323006C2 |
| PHARMACEUTICAL PREPARATION WITH IMMEDIATE RELEASE | 2003 |
|
RU2351314C2 |
| ESSENTIALLY CRYSTALLINE MELAGATRAN FORM | 2000 |
|
RU2243973C2 |
| NOVEL DERIVATIVES OF MANDELIC ACID AND THEIR USING AS THROMBIN INHIBITORS | 2001 |
|
RU2300521C2 |
| CRTH2 ANTAGONIST PARTICLES | 2008 |
|
RU2468012C2 |
| ALMOND ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITOR | 2002 |
|
RU2341516C2 |
| SOLID FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | 2013 |
|
RU2673077C2 |
| SOLID FORMS OF CEFTOLOZANE | 2014 |
|
RU2703457C2 |
